Antibodies - Sartobind® Rapid A Lab: Revolutionizing Antibody Purification
Can't see this email? View it online
   
  Antibodies Antibodies logo  
  The latest antibodies news from News Medical  
 

Solving Complex Stoichiometry: Antibody-Protein-Detergent InteractionsSolving Complex Stoichiometry: Antibody-Protein-Detergent Interactions

Binding stoichiometry is a crucial piece of information but is often inaccurate due to measurement bias. This case study tackles the challenge by using size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) to measure the stoichiometry of an antibody fragment, membrane protein, and detergent complex

Read the Application Note
 
 
    Sartobind® Rapid A Lab: Revolutionizing Antibody PurificationSartobind® Rapid A Lab: Revolutionizing Antibody Purification
 
Get ready for Sartobind® Rapid A Lab, the next-generation affinity chromatography consumable that purifies antibodies in seconds. With its speed, flexibility, and process-ready matrix, it’s designed to streamline workflows and simplify lab-to-commercial production transfer. Register now and be the first to know when it launches this fall!
 
Register Now
 
 
   Long-lived plasma cells fail to establish after COVID mRNA vaccination, limiting long-term antibody responseLong-lived plasma cells fail to establish after COVID mRNA vaccination, limiting long-term antibody response
 
Researchers found that SARS-CoV-2-specific plasma cells were largely excluded from the long-lived plasma cell compartment in the bone marrow after mRNA vaccination, explaining the short-lived antibody response.
 
   Innovative CAR-T cells effectively target glioblastoma with reduced toxicityInnovative CAR-T cells effectively target glioblastoma with reduced toxicity
 
Glioblastoma is the most common and most aggressive primary brain tumor, with an average survival after diagnosis of less than two years, and against which current treatments remain ineffective.
 
 Discovery of antibodies that boost complement activation against K. pneumoniae
 
Discovery of antibodies that boost complement activation against K. pneumoniaeResearchers investigate antibody-dependent complement activation during Klebsiella pneumoniae infection.
 
 
 New cell therapy offers effective treatment for patients with T-cell acute lymphoblastic leukemia
 
New cell therapy offers effective treatment for patients with T-cell acute lymphoblastic leukemiaA new cell therapy, targeting CD7 on leukaemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukaemia (T-ALL) who have exhausted all standard treatment options.
 
 
 Advancing Neuroscience: The Critical Role of High-Quality Antibodies in Neurodegenerative Research
 
Advancing Neuroscience: The Critical Role of High-Quality Antibodies in Neurodegenerative ResearchIn neuroscience, antibodies are essential for investigating neurodegenerative disorders, facilitating early diagnosis and potential therapeutic interventions.
 
 
 Revolutionizing Immunology Research with Advanced Antibody Profiling Tools
 
Revolutionizing Immunology Research with Advanced Antibody Profiling ToolsAntibody profiling tools enhance immunology research, offering insights into humoral responses and vaccine efficacy through high-throughput antigen analysis.
 
 
 Antibody engineering drives innovation in drug development
 
Antibody engineering drives innovation in drug developmentMonoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound annual growth rate (CAGR) of 11.07% from 2024 (237.64 billion USD estimated at the end of 2023) to 2033 (679.03 billion USD expected by the end of 2033).
 
 
 One-Third of Antibody Drugs Show Unintended Target Binding
 
One-Third of Antibody Drugs Show Unintended Target BindingIntegral Molecular, a leader in antibody discovery and characterization, has published new research in the journal mAbs, revealing that as many as one-third of antibody-based drugs exhibit nonspecific binding to unintended targets.
 
 
 UNC Researchers Unveil CAR-NKT Therapy for Enhanced Antitumor Activity
 
UNC Researchers Unveil CAR-NKT Therapy for Enhanced Antitumor ActivityIn the fight against cancer, chimeric antigen receptor T cell (CAR-T) therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors.
 
 
 Single-Cell Sequencing Reveals New Insights into Immune Cell Interactions
 
Single-Cell Sequencing Reveals New Insights into Immune Cell InteractionsA new review by Dr. Ruyuan Wang and an international team of researchers explores the complex interactions between the innate and adaptive immune systems, shedding light on regulatory mechanisms in infection, cancer, and autoimmune diseases.